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Abstract: Invasive meningococcal disease occurs worldwide causing an estimated 50,000–135,000 
deaths each year in addition to signiﬁ  cant sequelae. In developed countries the disease is usually 
sporadic but outbreaks and epidemics, usually due to serogroups B and C, have occurred. In the 
US, an increasing number of cases are due to serogroup Y. In developing nations, epidemics 
due to serogroups A and more recently W-135, are common. The tetravalent meningococcal 
conjugate vaccine to serogroups A, C, Y, and W-135 (MCV4) has been demonstrated to be 
highly immunogenic and promote immune memory. This article will describe the rationale for the 
vaccine and its potential role to signiﬁ  cantly decrease mortality and morbidity of meningococcal 
disease in those areas and populations at greatest risk from these serogroups.
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Epidemiology and pathogenesis
Neisseria meningitidis is an aerobic, gram negative diplococcus that colonizes the 
nasopharynx of humans and is transmitted by respiratory tract droplets (Gardner 2006). 
Almost all human disease is caused by 5 of the 13 serogroups: A, B, C, Y, and W-135. 
Worldwide, approximately 500,000 cases of invasive meningococcal disease (IMD) 
occur annually resulting in an estimated 50,000–135,000 deaths per year (Pollard 2004; 
Borrow and Miller 2006). The incidence of the disease in developed countries varies 
from 0.5 to 1.1 per 100,000 people per year in the US (Gardner 2006) to 3.6 cases per 
100,000 in England and Wales (Pollard 2004). In 2006, the estimated incidence of 
probable and conﬁ  rmed IMD varied from 0.30 and 0.35 per 100,000 people in Italy 
and Hungary, respectively, to 4.96 and 8.90 per 100,000 in Ireland and Malta, respec-
tively (EU-IBIS 2006). In the US, over 98% of cases of IMD are sporadic (Bilukha 
and Rosenstein 2005) but the disease is epidemic in many parts of the world.
The inﬂ  uence of serogroups in causing meningococcal disease varies according 
to year, geography, and, in some cases, ethnic and socioeconomic factors. Sero-
groups B and C cause most cases of sporadic and rare epidemic disease in developed 
countries. Serogroups B, C, W-135, and Y comprised 61%, 32.2% , 3.2%, and 2.9% 
of meningococcal isolates, respectively, from IMD patients in the Czech Republic, 
Greece, and Norway (Yazdankhah et al 2004). Among IMD isolates, serogroup B 
predominated in Greece and Norway while serogroup C predominated in in the Czech 
Republic (Yazdankhah et al 2004). Serogroup A and recently W-135 cause most cases 
of epidemic disease in sub-Saharan Africa (almost 1000 cases per 100,000 population) 
(Pollard 2004). Serogroup W-135 meningococcal disease has been reported in pilgrims 
returning from the Hajj in Saudi Arabia and in their contacts (MMWR 2001b; Hahne 
2002). Serogroup Y accounted for only 2% of meningococcal disease in the US from 
1988 to 1991 but accounted for 40% of cases during 2006, while serogroups B and C Therapeutics and Clinical Risk Management 2008:4(4) 740
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accounted for 28% and 27% during that year (CDC 2007). 
In New Zealand, an epidemic of predominantly serogroup B 
meningococcal disease has recorded disease rates as high as 
approximately 500 per 100,000 in Paciﬁ  c children less then 
1 year of age compared with less then 50 per 100,000 children 
of European descent (O’Hallahan et al 2004).
Invasive meningococcal disease usually occurs in persons 
who are seronegative and subsequently acquire N. menin-
gitidis from crowding such as among military recruits and 
freshmen college students living in residence halls (Bruce 
et al 2001). The nasopharyngeal carriage rate of N. men-
ingitidis has been shown to increase rapidly for ﬁ  rst year 
university students living in residence halls (Neal et al 2000). 
Exposure to tobacco smoke and alcohol-related behaviors are 
other potential risk factors for meningococcal disease in this 
population (Harrison et al 1999).
Once N. meningitidis attaches to the nasopharyngeal 
mucosal cells, replicates, and establishes a carrier state, 
multiple factors determine the occurrence of IMD includ-
ing the virulence of the organism and factors affecting host 
susceptibility (Granoff 2004). The spleen is responsible 
for clearing meningococci from the blood and anatomic 
splenectomy has resulted in overwhelming meningococcal 
sepsis (Condon et al 1994). Patients with functional hypo- 
or asplenia are also at increased risk for disease (Granoff 
2004). Deﬁ  ciencies of terminal complement component, 
properdin, factor D, and mannan-binding lectin (MBL) have 
been associated with increased susceptibility to meningo-
coccal infection (Pollard and Frasch 2001). The absence of 
serum bactericidal antibodies (SBAs) to human complement 
(hSBAs) to serogroup C meningococci, as demonstrated by 
a titer of less then 1:4, was associated with an increased risk 
of meningococcal disease in military recruits (Goldschneider 
et al 1969a). It was later demonstrated that SBAs to rabbit 
complement (rSBAs) with a titer of less then 1:8 also predict 
susceptibility to meningococcal disease (Borrow et al 2001). 
Conversely, a hSBA titer to serogroup C of 4 is considered 
protective while a rSBA titer of 8 is correlated with at least 
short-term protection (Borrow et al 2005).
Burden of illness
Vieusseux in Switzerland ﬁ  rst described epidemic menin-
gococcal disease in 1805, but Weichselbaum ﬁ  rst identiﬁ  ed 
the bacterium in 1887 (Barquet et al 1999; Rosenstein et al 
2001). Meningitis occurs in about 50% of patients, and in 
older children and adults is accompanied by sudden head-
ache, fever, stiff neck, and sometimes nausea, vomiting, 
and photophobia (Rosenstein et al 2001). In infants and 
very young children, fever, poor feeding, and lethargy may 
be seen initially while nuchal rigidity presents later in the 
course of the illness (Granoff 2004). A rash is often present 
but may vary from maculopapular to the classic petechial or 
purpuric rash. Meningococcal sepsis or meningococcemia 
occurs in 5%–20% of IMD (Rosenstein et al 2001). It is 
characterized by sudden fever, petechial or purpuric rash, 
hypotension progressing to shock, acute adrenal hemorrhage 
(Waterhouse-Friederichsen syndrome), and multiorgan fail-
ure (Rosenstein, Perkins et al 2001). Other forms of IMD 
include pneumonia, arthritis, pericarditis, and cellulitis (van 
Deuren et al 2000).
The overall case-fatality rate for IMD in the US is 
approximately 9%–12%, even with appropriate antibiotic 
treatment, and that for meningococcemia is as high as 40% 
(Rosenstein et al 2001). However, the fatality rate can vary 
according to the affected population and the meningococcal 
serogroup. In New Zealand, the average case-fatality rate 
for serogroup B IMD is 4.3% (O’Hallahan et al 2004). In 
a study of 295 cases of IMD in Maryland, USA from 1992 
to 1999, persons ages 15–24 years old accounted for 24% 
of IMD cases and had a fatality rate of 23% compared with 
4.6% of those younger than 15 years and 17% of those older 
than 24 years (Harrison et al 2001). Of the 14 fatalities for 
which serogroup was known, serogroups C and Y accounted 
for 57% and 29%, respectively, of fatalities in this age group 
(Harrison et al 2001). Consequently, more then 85% of 
these deaths were potentially preventable by the tetravalent 
(Groups A, C, Y, and W-135) meningococcal vaccines.
Invasive meningococcal disease may also cause sequelae 
such as hearing loss, neurologic deﬁ  cits, or limb loss in up 
to 11%–19% of cases (Rosenstein et al 2001). A review of 
IMD in Barcelona from 1987 to 1992 found a sequelae rate 
of 8.2% for meningitis, 3.5% for meningococcemia with 
meningitis, and 1.5% for meningococcemia with an overall 
rate of 4% (Barquet et al 1999). All patients who had neuro-
logic sequelae had meningitis while meningococcemia was 
associated with sequelae such as limb amputation (Barquet 
et al 1999).
Outbreaks of meningococcal disease
Household contacts of patients with IMD have a 500–800 
times greater risk of meningococcal disease than the general 
rate and should be given chemoprophylaxis (Bilukha and 
Rosenstein 2005). They are candidates for immunization 
with meningococcal vaccine, but this does not substitute for 
chemoprophylaxis because of the time delay in developing 
immunity. Chemoprophylaxis should also be given to close Therapeutics and Clinical Risk Management 2008:4(4) 741
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contacts including child-care center contacts, anyone directly 
exposed to the patient’s oral or respiratory secretions, and 
passengers who sat on either side of the index-patient on 
a ﬂ  ight lasting /= 8 hours (MMWR 2001a; Bilukha and 
Rosenstein 2005). Because systemic therapy other than 
ceftriaxone or other third-generation cephalosporin might 
not eradicate N. meningitidis from the nasopharynx, patients 
treated for IMD with other agents such as penicillin should 
also receive chemoprophylaxis (Abramson and Spika 1985; 
Bilukha and Rosenstein 2005). Chemoprophylaxis is ideally 
given within 24 hours of identiﬁ  cation in the index patient 
and is of little value 14 days after disease onset (Bilukha 
and Rosenstein 2005). Table 1 lists currently recom-
mended antibiotic prophylaxis for meningococcal disease. 
Fluoroquinolone-resistant N. meningitidis has been reported 
in Argentina, Australia, China, France, India, Spain, and most 
recently in the northern US (MMWR 2008). One study found 
azithromycin comparable in efﬁ  cacy to rifampin in eradicat-
ing nasopharyngeal coverage of N. meningitis (Girgis 1998). 
When ﬂ  uoroquinolone-resistant meningococcal disease is 
identiﬁ  ed, interim CDC recommendations are to give a single 
dose of 500 mg azithromycin for exposed persons 15 years 
old or 10 mg/kg body weight for those under 15 years old 
(MMWR 2008).
The United States Centers for Disease Control and Pre-
vention (CDC) deﬁ  ne outbreaks as three or more conﬁ  rmed 
or probable cases of meningococcal disease in 3 months 
among persons residing in the same area who are not close 
contacts of each other with a primary disease attack rate of 
10 cases/100,000 persons (Bilukha and Rosenstein 2005). 
In the circumstance of a conﬁ  rmed outbreak, public health 
personnel should consider vaccinating the population at risk. 
Mass chemoprophylaxis is not recommended except for 
outbreaks involving populations in a limited setting such as 
school or for a serogroup B outbreak in those countries where 
a vaccine is not available (Bilukha and Rosenstein 2005).
Meningococcal polysaccharide 
vaccines
Goldschneider and colleagues demonstrated that transplacen-
tal passage of antibodies to meningococci occurred resulting 
in passively acquired immunity to infection (Goldschneider 
et al 1969b). In addition they found that military recruits 
developed bactericidal antibodies to their own meningococ-
cal isolates as a response to their carrier state (Goldschneider 
et al 1969b). Animal and human testing subsequently demon-
strated that serogroups A and C polysaccharides stimulated 
immunogenicity (Gotschlich et al 1969). This led to the 
development of polysaccharide vaccines that were effective 
in preventing group C disease in US military recruits and 
controlling group A epidemics in Africa (Jodar et al 2002). 
The tetravalent polysaccharide vaccine to serogroups A, C, Y, 
and W-135 (MPSV4, Menomune®-A,C,Y,W-135, Sanoﬁ   
Pasteur, Inc., Swiftwater, Pennsylvania, US) was 85% efﬁ  ca-
cious in preventing group C meningococcal disease during 
an outbreak in Texas, USA (Rosenstein et al 1998).
The MPSV4 vaccine is T cell-independent and the sero-
group C component is poorly immunogenic in children less 
then 18–24 months old while the serogroup A polysaccharide 
does not induce an immune response comparable to adults 
until ages 4–5 years (MMWR 2000). In children less then 
5 years, antibody levels to group A and C polysaccharides 
decrease signiﬁ  cantly within 3 years after a single vaccine 
dose (MMWR 2000). The vaccine also does not stimulate 
immune memory, and revaccination with serogroup C capsu-
lar polysaccharide vaccines often results in a hypo-responsive 
Table 1 Chemoprophylactic agents for meningococcal disease
Drug  Age group  Dosage and route  Duration
Rifampina Children  1 month  5 mg/kg orally every 12 h  2 days
(Rifadin) Children  1 month  10 mg/kg orally every 12 h  2 days
  Adults  600 mg orally every 12 h  2 days
Ciproﬂ  oxacinb (Cipro®)  Adults  500 mg orally  Single dose
Ceftriaxone (Rocephin®) Children  15 years  125 mg intramuscularly  Single dose
 Persons  15 years  250 mg intramuscularly  Single dose
Azithromycinc Children  15 years  10 mg/kg body weight  Single dose
 Persons  15 years  500 mg  Single dose
aRifampin is not recommended for pregnant women because it is teratogenic in laboratory animals. It may decrease the effectiveness of other medications, including oral 
contraceptives, and alternative contraceptive methods are recommended during its use.
bCiproﬂ  oxacin is not usually recommended for persons aged 18 years or for pregnant and lactating women because it causes cartilage damage in immature laboratory animals; 
however, it can be used for chemoprophylaxis of children when no acceptable alternative therapy is available.
cAzithromycin is recommended as an alternative agent for chemoprophylaxis in certain areas of the US (North Dakota and Minnesota) where ﬂ  uoroquinolone-resistant 
meningococcal disease has been identiﬁ  ed.
Derived from Bilukha and Rosenstein (2005) and MMWR (2008).Therapeutics and Clinical Risk Management 2008:4(4) 742
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antibody response to group C polysaccharide in children 
and adults (Granoff et al 1998; MacDonald et al 1998; 
Danzig 2004). It has been posited that repeated stimulation 
of B cells with the T-cell independent plain polysaccharide 
vaccine results in terminal differentiation of B cells to pro-
duce plasma cells and depletes the pool of speciﬁ  c B cells 
(Granoff and Pollard 2007).
The serogroup B meningococcal polysaccharide is poorly 
immunogenic and the resulting IgG antibodies have poor 
complement bactericidal activity. In addition, the serogroup 
B capsular polysaccharide is structurally similar to a nerve cell 
molecule present in developing neural tissue and small amounts 
of adult tissue (Danzig 2004). Vaccines for serogroup B that 
utilize the outer membrane vesicle (OMV) of N. meningitidis 
are under trial in a number of countries (Borrow et al 2005). 
Their use is beyond the scope of this article.
The United Kingdom (UK) 
experience with conjugate 
meningococcal C vaccine
Polysaccharides conjugated to carrier proteins induce T-cell 
dependent immunity (Granoff 2004). In November, 1999, 
the UK initiated a program to vaccinate all children with 
conjugate meningococcal C vaccine. Two vaccine brands 
used CRM197 as the carrier protein (Wyeth and Novartis, 
Canada, QC) and one used tetanus toxoid (Baxter Biosci-
ence, IL, USA) (Borrow and Miller 2006). The vaccine was 
given to infants at 2, 3, and 4 months of age, with a single 
dose catch-up to all children ages 1–18 years old and two 
doses for infants 5–11 months old (Borrow and Miller 2006). 
These vaccines were demonstrated to be immunogenic and 
efﬁ  cacious in infants, children, and adolescents. The number 
of cases of serogroup C IMD in adolescents 15–17 years old 
decreased by 76% from Jan 1 to Sept 30, 2000 compared with 
the corresponding period in 1999 and vaccine efﬁ  cacy was 
estimated at 97% in teenagers (Ramsay et al 2001). Cases of 
serogroup C IMD in toddlers decreased by 34% during this 
period, but vaccine efﬁ  cacy was estimated at 92% (Ramsay 
et al 2001). More than 1 year later, vaccine effectiveness 
decreased signiﬁ  cantly in infants 2–4 months at initial immu-
nization while effectiveness in older children and especially 
adolescents persisted (Trotter et al 2004).
The nasopharyngeal carriage of meningococcal serogroup 
C bacteria in students aged 15–17 years was found to decrease 
by 66% 1 year later (Maiden and Stuart 2002). The attack rate 
of serogroup C IMD subsequently decreased by 67% overall 
in un-immunized children and adolescents from July 2001 to 
June 2002 compared with July 1998 to June 1999 (Ramsay 
et al 2003). Consequently, there is evidence of herd immunity 
in unvaccinated members of the population or those in whom 
antibody levels have waned if a high enough proportion of 
the population is vaccinated.
Safety and efﬁ  cacy 
of the tetravalent meningococcal 
conjugate vaccine
Three separate groups of 30 healthy US adults ages 18–55 
years were given a single dose of tetravalent meningococcal 
conjugate vaccine containing either 1, 4, or 10 μg of each 
capsular polysaccharide conjugated to diphtheria toxoid. 
Twenty-eight days after immunization, the percentage of 
recipients with SBA titers of 8 was 100%, 89%–100%, 
88%, and 91% for serogroups A, C, Y, and W-135, respec-
tively (Campbell et al 2002). Mild to moderate local reactions 
such as injection site erythema and swelling occurred in over 
50%–90% of subjects and in each dose group, 41%–50% 
reported at least one systemic reaction such as headache and 
malaise. One subject experienced severe pain, chills, and 
malaise with local tenderness and vomiting that resolved 
within 2 days (Campbell et al 2002). Another study random-
ized over 800 adolescents (ages 11–18 years) to MPSV4 
or the meningococcal conjugate vaccine containing 4 μg 
of capsular polysaccharide each from serogroups A, C, Y, 
W-135 (MCV4). Both vaccines were highly immunogenic to 
all four serogroups, although the MCV4 recipients reported 
more local reactions than the MPSV4 group (69% vs 30%) 
(Keyserling et al 2005). Follow-up at 3 years demonstrated 
persistence of SBA and booster responses to MCV4 consis-
tent with immune memory that was not present in the MPSV4 
group (Keyserling et al 2005). In January 2005, the US Food 
and Drug Administration (FDA) licensed Meningococcal 
Polysaccharide (serogroups A, C, Y, and W-135) Diphthe-
ria Toxoid Conjugate Vaccine (MCV4, Menactra®, Sanoﬁ   
Pasteur, Inc., Swiftwater, PA, US) for the immunization of 
adolescents and adults aged 11–55 years age (Bilukha and 
Rosenstein 2005).
A US study compared safety and immunogenicity of 
MCV4 with MPSV4 in 2- to 10-year-old children. The 
percentage of children with SBA titers 1/128 ranged 
from 81%–97% across the 4 serogroups in the MCV4 
group versus 73%–93% for the MPSV4 group (Pichichero 
et al 2005). Mild to moderate local and systemic reactions 
of short duration were common and comparable in both 
groups (Pichichero et al 2005). A subgroup of children vac-
cinated with MCV4 were given a challenge dose of MPSV4 
23–36 months later. They demonstrated an increase in IgG Therapeutics and Clinical Risk Management 2008:4(4) 743
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antibody and antibody avidity consistent with the induction 
of immune memory (Pichichero et al 2006). A UK study 
gave MCV4 to children 2 to 5 years old who had previ-
ously received the monovalent meningococcal C conjugate 
vaccine. All 44 children developed SBA titers 8 to all four 
serogroups with a booster response observed to serogroup 
C (El Bashir et al 2006). In October, 2007 the FDA subse-
quently licensed MCV4 for use in children aged 2–10 years 
(MMWR 2007).
Another study compared vaccine doses of 1, 4, and 10 μg 
for each of the four polysaccharide serogroups conjugated 
to diphtheria toxoid that were given to infants at 2, 4, and 
6 months of age. Presumed protective SBA levels /= 1:8 
varied from 54% to 92% 1 month after the primary series 
depending upon vaccine serogroup and polysaccharide dose. 
A polysaccharide content of 10 μg was associated with more 
frequent local reactions but not with a corresponding increase 
in immunogenicity than lower doses of each serogroup 
(Rennels et al 2004). Consequently, there is no advantage 
to having a higher dose of the polysaccharide serogroups in 
the diphtheria toxoid conjugate vaccine.
Guillain-Barré Syndrome (GBS) among 
MCV4 recipients
In October 2005, reports suggested a possible association of 
GBS with MCV4, and the ACIP recommended that persons 
with a past history of GBS not be vaccinated with MCV4 
unless they are at high risk for meningococcal disease 
(MMWR 2006). As of October 2007, there were 24 con-
ﬁ  rmed reports of GBS after administration of MCV4 to the 
US Vaccine Adverse Event Reporting System (Clark 2007). 
However, no cases of GBS were reported among 11- to 
19-year-olds within 6 weeks after more then 200,000 doses 
of MCV4 from the Vaccine Safety Datalink project (Clark 
2007). The excess risk of GBS is currently estimated to be 
from 0.4 to 1.3 per million doses (Clark 2007). The beneﬁ  ts 
of MCV4 are currently considered to signiﬁ  cantly outweigh 
the potential risks, except in patients with a prior history of 
GBS (see contraindications and precautions).
Indications for use of MCV4
Table 2 lists the recommendations for the use of MCV4 made 
by the CDC Advisory Committee on Immunization Practices. 
It is routinely recommended for all US children aged 11–18 
years, including those at additional risk. The vaccine is now 
recommended for use in at-risk children ages 2–10 years 
(MMWR 2007) and at-risk adults aged 19–55 years. Persons 
aged 2–55 years who continue to be at risk for meningococcal 
infection, despite having been vaccinated with MPSV4 3 
or more years earlier, are also candidates for revaccination 
with MCV4 (Bilukha and Rosenstein 2005). The FDA has 
not approved the vaccine for use in children younger then 2 
years or adults older then 55 years. Consequently MPSV4 
could be substituted for adults older than 55 years.
Contraindications and precautions 
to use of MCV4
Administration of MCV4 is contraindicated among persons 
known to have a severe allergic reaction to any component 
of the vaccine, including diphtheria toxoid or to natural latex 
rubber. MCV4 is an inactivated vaccine and may be given to 
immunosuppressed persons, but this may result in subopti-
mal immune response. No data are available about its safety 
during pregnancy (Bilukha and Rosenstein 2005). A history 
of GBS is considered a precaution to administering MCV4, 
and MPSV4 is an acceptable short-term alternative providing 
protection for approximately 3–5 years (MMWR 2007).
Cost effectiveness of MCV4
Cost effectiveness of meningococcal vaccination has been 
somewhat controversial, especially with the polysaccharide 
MPSV4 vaccine in developed countries where the vast 
majority of meningococcal cases are sporadic. One analysis 
estimated that vaccinating all US college freshmen living in 
dormitories with MPSV4 would cost US$0.6–$1.9 million 
per case averted and US$7–20 million per death averted 
Table 2 Recommendations for use of tetravalent (A, C, Y, W-135) 
meningococcal conjugate vaccine
Population type  Ages (years)
Routine vaccination 
  All persons aged 11–18 years  11–18
Persons at increased risk for meningococcal disease 
  College freshmen living in dormitories  19–55
 Military  recruits  19–55
   Microbiologists routinely exposed to isolates  19–55
of Neisseria meningitidis 
   Persons with anatomic or functional asplenia or  2–55
terminal complement deﬁ  ciencies 
   Travelers to or residents of countries in  2–55
which N. meningitidis is hyperendemic or epidemic,
especially sub-Saharan Africa
during the dry season (December–June) or
Saudi Arabia during the Hajj
  Persons infected with HIVa 2–55
aPersons with human immunodeﬁ  ciency virus (HIV) are likely at increased risk of menin-
gococcal disease, although not to the extent that they are at risk for invasive Streptococcus 
pneumoniae infection. The efﬁ  cacy of MCV4 among HIV-infected persons is unknown.
Derived from Bilukha and Rosenstein (2005) with update from MMWR (2007).Therapeutics and Clinical Risk Management 2008:4(4) 744
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(Scott 2002). This analysis did not consider the cost of 
chemoprophylaxis or vaccination in the event of an outbreak, 
the cost of rehabilitating IMD survivors with sequelae, and 
the anxiety and stress due to an outbreak in the university 
community (Scott 2002). It has been estimated that routine 
vaccination of US adolescents 11 years old with MCV4 
would prevent 270 cases of meningococcal disease and 
36 deaths over 22 years at a cost of US$633,000 per case 
and US$121,000 per life-year saved (Shepard et al 2005). 
Although ﬁ  nancial costs of prevention are high, the mortal-
ity and morbidity of IMD warrant the routine use of MCV4 
in adolescents.
Conclusion and future issues
In addition to the devastation of the disease, considerable 
anxiety often accompanies an outbreak of IMD in the com-
munity or affected regions. The MCV4 has demonstrated 
immunogenicity to serogroups A, C, Y, and W-135 with an 
acceptable degree of reactogenicity. Based on the experi-
ence with conjugated meningococcal C vaccine in the UK, 
it is believed that MCV4 will have a similar impact on IMD 
caused by those serogroups. Because it is a conjugate vaccine, 
it is believed that the immunity provided by this vaccine will 
last longer then that provided by MPSV4. However, data 
suggest that serologic correlates of immunity to serogroup 
C may wane rapidly after 1 year in young children (Snape 
et al 2005; Borrow and Miller 2006). The conjugate vaccines 
prime for immune memory but it is not clear that this occurs 
quickly or sufﬁ  ciently enough to provide protection from 
disease (Borrow and Miller 2006). Protection from disease 
may therefore depend on persistence of protective antibody 
levels and herd immunity. Thus far, antibody persistence in 
older children and adolescents appears good but it remains 
to be seen whether a booster dose of vaccine will be required 
at some future date.
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